{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_6989375_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"008-827-537-360-791"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11646,"type":"PATENT","title":"UT M. D. Anderson Cancer Center - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4091,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8312,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
(a) contacting said dividing cell with a DNA-damaging agent; and\n
(b) transferring said transgene into said dividing cell between greater than about 1 day and less than or equal to 4 days after contacting said dividing cell with said DNA damaging agent."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said target cell is a tumor cell."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said tumor cell is cisplatin sensitive."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said tumor cell is cisplatin insensitive."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said DNA-damaging agent is selected from the group consisting of cisplatin, carboplatin; VP16, teniposide, daunorubicin, doxorubicin, dactinomycin, mitomycin, plicamycin, bleomycin, procarbazine, nitrosourea, cyclophosphamide, bisulfan, melphalan, chlorambucil, ifosfamide, merchlorehtamine, and ionizing radiation."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said transgene is transferred at about 2 days after contacting said dividing cell with said DNA-damaging agent."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said transfer of said transgene is accomplished by a technique selected from the group consisting of liposome-mediated transfection, receptor-mediated internalization and viral infection."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said transgene is a tumor suppressor gene."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8, wherein said tumor suppressor gene is p53."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein said p53 transgene is under the transcriptional control of a promoter."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said promoter is a CMV IE promoter."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11, wherein said transgene is regulated by a polyadenylation signal."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein said polyadenylation signal is an SV40 polyadenylation signal."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said p53 transgene is carried in an adenoviral vector."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said contacting of said DNA-damaging agent with said dividing cell is discontinued and wherein said transgene is transferred into said dividing cell between greater than about 1 day and less than or equal to 3 days after said contacting of said DNA-damaging agent with said dividing cell is discontinued."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method for enhancing the expression of a transgene in a target neoplastic cell in vivo, comprising:\n
(a) administering a DNA-damaging agent to a subject containing a target neoplastic cell; and\n
(b) transferring said transgene into said target cell between greater than about 1 day and less than or equal to 4 days after said administering step."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said target neoplastic cell is cisplatin sensitive."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said target neoplastic cell is cisplatin insensitive."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said DNA-damaging agent is selected from the group consisting of cisplatin, carboplatin; VP16, teniposide, daunorubicin, doxorubicin, dactinomycin, mitomycin, plicamycin, bleomycin, procarbazine, nitrosourrea, cyclophosphamide, bisulfan, melphalan, chlorambucil, ifosfamide, merchloroehtamine, and ionizing radiation."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said transgene is transferred at about 2 days after contacting said target cell with said DNA-damaging agent."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said transfer of said transgene is accomplished by a technique selected from the group consisting of liposome-mediated transfection, receptor-mediated internalization and viral infection."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said transgene is a tumor suppressor."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein said tumor suppressor is p53."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 23, wherein said p53 transgene is under the transcriptional control of a promoter."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 24, wherein said promoter is a CMV IE promoter."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein said transgene is regulated by a polyadenylation signal."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein said polyadenylation signal is an SV40 polyadenylation signal."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein said p53 transgene is carried in an adenoviral vector."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said DNA-damaging agent is removed from said cell and wherein said transgene is transferred into said target cell between greater than about 1 day and less than or equal to 3 days after removing said DNA-damaging agent."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["A method for enhancing the expression of a transgene in a target neoplastic cell in vitro, comprising:\n
(a) contacting said target neoplastic cell with a DNA-damaging agent;\n
(b) transferring said transgene into said neoplastic cell between greater than about 1 day and less than or equal to 4 days after said contacting step, whereby expression of the transgene is enhanced as the result of the treatment of said target neoplastic cell with said DNA-damaging agent."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 30, further comprising removing said DNA-damaging agent from said target neoplastic cell and transferring said transgene into said target neoplastic cell between greater than about 1 day and less than or equal to 3 days after removing said DNA damaging agent."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 31, wherein said target neoplastic cell is cisplatin insenstitive."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 31, wherein said DNA-damaging agent is selected from the group consisting of cisplatin, carboplatin; VP16, teniposide, daunorubicin, doxorubicin, dactinomycin, mitomycin, plicamycin, bleomycin, procarbazine, nitrosourrea, cyclophosphamide, bisulfan, melphalan, chlorambucil, ifosfamide, merchloroehtamine, and ionizing radiation."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 31, wherein said transgene is transferred at about 2 days after contacting said target cell with said DNA-damaging agent."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 31, wherein said transfer of said transgene is accomplished by a technique selected from the group consisting of liposome-mediated transfection, receptor-mediated internalization and viral infection."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 31, wherein said transgene is a tumor suppressor."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 36, wherein said tumor suppressor is p53."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 37, wherein said p53 transgene is under the transcriptional control of a promoter."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 38, wherein said promoter is a CMV IE promoter."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 39, wherein said transgene is regulated by a polyadenylation signal."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40, wherein said polyadenylation signal is an SV40 polyadenylation signal."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 41, wherein said p53 transgene is carried in an adenoviral vector."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 30, wherein said DNA-damaging agent is removed from said target neoolastic cell and wherein said transgene is transferred into said target neonlastic cell between greater than about 1 day and less than or equal to 3 days after removing said DNA-damaging agent."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein said contacting of said DNA-damaging agent with said dividing cell is discontinued by ceasing administration of said DNA-damaging agent."],"number":44,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}